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DIRECT EFFECTS OF HIGH GLUCOSE
Aldose reductase and the role of the polyol pathway in
diabetic nephropathy
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Aldose reductase and the role of the polyol pathway in diabetic system for the disease has been elaborated [3, 4]. How-
nephropathy. ever, the mechanism(s) by which hyperglycemia causes
Background. In diabetic renal complications, hyperglycemia these complications remains controversial. This is be-may cause damage at a cellular level in both glomerular and
cause of the interrelated nature of the metabolic path-tubular locations, often preceding overt dysfunction. Our previ-
ways used in the presence of the raised level of glucose,ous work has implicated aldose reductase in a pathway whereby
aldose reductase-induced use of nicotinamide adenine dinucle- most importantly, in tissues in which glucose uptake does
otide phosphate (reduced form) (NADPH) drives the pentose not depend on insulin and glucose is converted to both
phosphate pathway, which culminates in a protein kinase enzymatic and nonenzymatic products [5]. The enzymeC–induced increase in glomerular prostaglandin production
aldose reductase (AR), which catalyzes the reductionand loss of mesangial cell contractility as a possible cause of
of glucose to sorbitol in the polyol pathway, has beenhyperfiltration and glomerular dysfunction in diabetes. In this
model, aldose reductase inhibition in vitro redresses all aspects extensively studied for a potential role in the develop-
of the pathway proposed to lead to hyperfiltration; aldose re- ment of microvascular complications, including early dia-
ductase inhibition in vivo gives only a partial amelioration
betic nephropathy. A published finding of an increaseover the short-term or is without effect in the longer term
in aldose reductase mRNA in patients with type 1 diabe-on microalbuminuria, which follows glomerular and tubular
dysfunction. In diabetes, hyperglycemia-induced renal polyol tes and nephropathy but not in patients with diabetes
pathway activity does not occur in isolation but instead in without nephropathy, is consistent with the degree of
tandem with oxidative changes and the production of reactive aldose reductase gene expression that modulates the risk
dicarbonyls and a,b-unsaturated aldehydes. Aldose reductase
for nephropathy [6]. However, in human studies, aldosemay detoxify these compounds. We investigated this aspect in
reductase inhibitors have only a partial effect in amelio-a transgenic rat model with human aldose reductase cDNA
under the control of the cytomegalovirus promoter with tubular rating renal microvascular complications. A study of 6
expression of transgene. months’ administration of an aldose reductase inhibitor
Methods. Tubules (S3 region-enriched) from transgenic and had an effect on hyperfiltration in the presence of nor-control animals were prepared, exposed to oxidative stress, and
moalbuminuria [7], other studies have altered the courseanalyzed to determine the cellular protein dicarbonyl content.
of microalbuminuria [8] whereas several others haveResults. In tubules from transgenic animals, oxidative stress–
induced dicarbonyls were significantly reduced, an effect not proven negative [9, 10]. Such negative findings have fu-
seen when an aldose reductase inhibitor was present. eled a controversy surrounding the contribution of the
Conclusions. Aldose reductase may both exacerbate and al- aldose reductase enzyme but are difficult to interpret,leviate the production of metabolites that lead to hyperglyce-
considering the multiple cell types within renal tissue,mia-induced cellular impairment, with the balance determining
potential differences in aldose reductase expression, thethe extent of dysfunction.
long time-course for development of complications, and
the relatively short length of human trials and variable
The Diabetes Control and Complications Trial [1] potency and penetration of inhibitors. Moreover, those
and the United Kingdom Prospective Diabetes Study [2] factors that perpetuate or extend changes in damaged
strongly implicate hyperglycemia in the pathogenesis tissues may differ from the initial pathogenic mechanisms
and progression of microvascular complications in type 1 and the latter may not be addressed using intervention
and type 2 diabetes. The clinical course of diabetic ne- studies. The hyperglycemia-related factors that may initi-
phropathy has been described in detail and a grading ate the early renal functional changes of hypertrophy, hy-
perfiltration, and subsequent microalbuminuria have most
often focused on the glomerulus. However, both glomeru-Key words: Aldose reductase, polyol pathway, oxidative stress, car-
bonyl stress, transgenesis, diabetes mellitus. lar and tubular impairment may coexist. Acute tubular
epithelial cell hypertrophy contributes to diabetes-modi-Ó 2000 by the International Society of Nephrology
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fied renal growth [11]. Additionally, significantly in-
creased excretion of proximal tubule proteins can be
found in type 1 diabetes, whereas albuminuria, a marker
of glomerular impairment, remains within the normal
range [12]. Progressive diabetic kidney disease involves
glomerular, tubular, and tubulointerstitial injury [13].
The interrelated pathways that may contribute to early
pathogenesis in the presence of raised glucose levels in
the kidney are the aldose reductase (polyol formation)
pathway, de novo synthesis of diacylglycerol, nonenzy-
matic glycation, glucose autoxidation, and dicarbonyl or
lipid peroxidative stress.
Aldose reductase (polyol formation) pathway
The polyol pathway involves two enzymatic reactions:
the first is the reduction of glucose to sorbitol by the
action of aldose reductase and the second oxidation of
sorbitol to fructose by the action of sorbitol dehydroge-
nase. Several studies on the renal location of aldose re-
ductase have been published. Despite some discrepan-
Fig. 1. The effect of the polyol pathway on pyridine nucleotide fluxcies, a general consensus exists that immunoreactive rat
and metabolism of glucose. The metabolism of glucose to sorbitol andaldose reductase is greatest in the medulla at the inner
fructose in the polyol pathway by aldose reductase (AR) and sorbitol
stripe of the outer medulla, the inner medulla, and at dehydrogenase (SDH), respectively, alters cytosolic pyridine nucleo-
tides to provide an increased ratio of NADP1/NADPH and NADH/the papillary tip [14]. Although relatively little immuno-
NAD1. Utilization of NADPH provides conditions for sustained actionreactive aldose reductase is observed in the cortex or the
of the pentose phosphate pathway (PPP) whereas use of NAD1 may
proximal tubules, aldose reductase activity is reported in inhibit formation of 1, 3 bisphosphoglycerate (1,3 BPG) from glycer-
aldehyde-3-phosphate resulting in an increased triose phosphate pool.both the cortex and outer medulla [15]. In renal mesan-
HK, hexokinase.gial and proximal tubule cells, the accumulation of sorbi-
tol can be demonstrated by elevated glucose concentra-
tions; its accumulation has been proposed as a mechanism
for altered cellular myoinositol level [16] and reduced function [23, 24]. Increased use of NADPH by activity
of aldose reductase could alter cellular metabolism in sev-Na1/K1-ATPase activity [17], each with a potentially
detrimental effect in diabetes. However, in the cells of eral ways, consequent in part on the stimulation provided
to the pentose phosphate pathway. As the oxidative reac-the inner medulla, sorbitol may function, together with
betaine [18] and glycerophosphorylcholine [19], as part tions of the pentose phosphate pathway are inhibited by
NADPH, its consumption in aldose reductase–activatedof the organic osmolyte defense against extracellular sol-
ute fluctuations. Fructose, the second product of polyol conversions provides the conditions for a constant through-
put of glucose to provide pentose phosphate pathway inter-pathway is increased several fold in tissues with an acti-
vated polyol pathway [20, 21] and can contribute to non- mediates. Flux through the pentose phosphate pathway
may be favored further if an increased NADH:NAD1enzymic fructosylation of proteins and provide 3-deoxy-
glucosone, the precursor to advanced glycation end ratio inhibits the NAD1-requiring enzyme glyceraldehyde-
3-phosphate dehydrogenase, preventing 1,3-bisphospho-products [22]. After formation of polyol pathway prod-
ucts, important alterations in the ratio of reduced pyri- glycerate formation from glyceraldehyde-3-phosphate in
glycolysis [25, 26]. These pathways are summarized indine nucleotides result from flux through the polyol path-
way. Reduction of glucose to sorbitol uses NADPH and Fig. 1. In part, activation of the pentose phosphate path-
way supplies the increased requirements for ribose 5-phos-oxidation of sorbitol increases NADH with a resultant
rapid change in the cytoplasmic redox state. Decreased phate and NADPH for biosynthetic reactions occurring
with renal hypertrophy in experimental diabetes [27].NADPH (altered cytosolic ratio of NADPH:NADP1)
may compromise reduction of glutathione in oxidatively
De novo synthesis of diacylglycerolstressed cells. Increased formation of NADH, following
oxidation of sorbitol to fructose, favors a condition of It has been shown that glucose can be metabolized di-
rectly to diacylglycerol, by a process involving conversionhyperglycemia-induced pseudohypoxia in diabetic tissue
whereby abnormalities accompanying the increase in the of triose phosphate intermediates produced when glu-
cose-6-phosphate is used by glycolysis or the pentoseratio of NADH:NAD1, without a decrease in pO2, bear
close parallels to the effects of true hypoxia on vascular phosphate pathway. Production of diacylglycerol is the
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presumed mechanism for the elevated protein kinase C sine, malondialdehyde-lysine and 4-hydroxynonenal and
acrolein-protein adducts [39–42] as detailed below.activity observed in several tissues obtained from dia-
betic animals or those that are exposed in vitro to high
Free radical, oxidative, and carbonyl stress in diabetesglucose concentrations [28, 29]. We have shown that one
Considerable evidence suggests generation of free rad-consequence of potential importance in the pathogenesis
ical species in the diabetic state, which may be broughtof diabetic complications is increased prostaglandin syn-
about by a coordinated increase in production and inthesis as a consequence of protein kinase C activity.
impaired free radical scavenging. In the pathways pre-Increased phospholipase A2, supplying the arachidonic
viously discussed, free radicals may arise from multipleacid precursor to prostaglandins, has been shown in glo-
pathways including autoxidation of glucose, hydrogenmeruli and mesangial cells from diabetic rats and its
peroxide (H2O2) generated from the oxidation of enedi-increased activation attributed to activation of protein
ols formed from Amadori products [41] or superoxidekinase C [30]. It seems likely that overproduction of
(O2x) formed by the mitochondrial oxidation of NADHvasodilatory prostaglandins by renal glomeruli plays a
to NAD1 [43] or in the formation of prostaglandins, asrole in early renal hyperperfusion and hyperfiltration. A
the PGH synthase reaction utilizes NADH (and NADPH)link between the aldose reductase pathway and prosta-
with the generation of O2x [44]. Both H2O2 and hydroxylglandin synthesis is demonstrated by the reversal by al-
radicals (xOH) may be derived from O2x. Several studiesdose reductase inhibitors of increased glomerular pen-
show the capacity of glomerular and tubule cells to gen-tose phosphate pathway activity and the protein kinase
erate reactive oxygen species with potential to imposeC and phospholipase A2 activation seen with raised glu-
a free radical stress [45, 46]. This stress may be modifiedcose [30] and by their inhibitory effect on vasodilatory
depending on the effective disposal of free radical speciesprostaglandin production in the glomerulus in experi-
within specific cell types [47, 48]. Levels of H2O2 maymental diabetes [31].
be decreased by the action of catalase or glutathione
peroxidase. This latter enzyme requires an effective cel-Nonenzymatic glycation
lular level of reduced glutathione. Regeneration of re-Nonenzymatic glycosylation of protein begins with the
duced glutathione requires and it has been contendedcovalent attachment of glucose to reactive amino groups
that as aldose reductase-catalyzed reduction of sub-at a rate determined by blood glucose concentrations.
strates, including glucose, uses NADPH, this places aThese early glycation products (Schiff bases and Ama-
demand on the cellular glutathione system for reductiondori products) can serve as precursors to advanced glyca-
of free radicals. This would apply to all aldose reductase-
tion products with complex glucose-derived cross-linking
catalyzed reactions. The concept of oxidative stress, as
altering the structure and function of cells and supporting distinct from carbonyl stress, has received considerable
matrix [32]. Alteration in the function of various micro- interest in diabetic vascular complications and investiga-
vascular and macrovascular cells are induced by interac- tions have been concerned primarily with the formation
tions with advanced glycation product–modified matrix of intracellular adducts of lipid and glucose products,
proteins. Albumin modified by Amadori glucose adducts their mode of production, and the contribution to ad-
activates type IV collagen gene transcription in glomeru- vanced glycation products and cellular stress. This has
lar mesangial cells [33]. Plasma levels of Amadori albu- been the subject of two recent extensive reviews [39, 40].
min are increased in type 1 diabetes [34] and have been The distinction between oxidative stress and carbonyl
shown to be significantly independently associated with stress stems from whether cellular damage is imposed
nephropathy classified by persistent albuminuria [35]. by oxidative products or occurs nonoxidatively [39].
Aminoguanidine treatment, which reduces glomerular Dicarbonyl species formed without oxidation include
basement membrane–advanced glycation product con- methylglyoxal, which forms nonoxidatively from triose
tent, ameliorates mesangial expansion and albuminuria phosphates and 3-deoxyglucosone, itself formed by the
[36]. Moreover, nonenzymatic glycation of reactive amino nonoxidative 1,3-enolation of Amadori adducts and from
groups in model proteins increases the rate of free radical fructose. From these active precursors, glycated or gly-
production nearly 50-fold [37], providing a link with oxi- coxidated protein adducts are formed contributing to
dative changes described in the next sections. the advanced glycation end (AGE) products of diabetes
[39–42]. Carboxymethyllysine adducts of protein have
Glucose autoxidation and glycoxidation been shown recently to be signal-tranducing ligands for
Trace metal–catalyzed oxidation of glucose can form one receptor recognizing advanced glycation end prod-
reactive oxygen species [38]. The oxidative modification ucts, the receptor for advanced glycation end product
of carbohydrates, lipids and proteins that follows can pro- (RAGE), with receptor-dependent modification of gene
duce glycoxidation and advanced glycation end products expression [49]. This follows the demonstration of ele-
vated serum levels of carboxymethyllysine in serum ofsuch as pentosidine, carboxymethyllysine, carboxyethylly-
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Fig. 2. Glucose, dicarbonyl and lipid dialdehyde
substrates for aldose reductase. In addition to
the formation of sorbitol from glucose, aldose
reductase uses several substrates that, in addition
to their nonenzymatic formation, can be formed
enzymatically following increased polyol pathway
activity. These include the reactive dicarbonyl sugar,
methylglyoxal, formed as an intermediate of the
glycolytic by-pass system from dihydroxyacetone
phosphate (DHAP) to lactate and 3-deoxygluco-
sone formed from fructose-3-phosphate (F-3-P).
In addition, 4-hydroxynonenal and acrolein, which
can be formed as aldehyde by-products of the
peroxidation of membrane fatty acids, are aldose
reductase substrates. The products of aldose re-
ductase activity are shown. The figures indicated
by the asterisk (*) are the reported specific activity
for recombinant human aldose reductase against
each substrate [53].
patients with diabetes and the immunohistochemical lo- idation in diabetes are outlined in Fig. 3. Because it may
be possible in some tissue sites to propose a protectivecalization of this marker of glycoxidation together with
rather than damaging role for aldose reductase, its regu-malondialdehyde-lysine and 4-hydroxynonenal adducts
lated expression may be an important determinant ofin the expanded mesangial area, capillary walls, and glo-
the balance between these functions.merular nodular lesions of renal biopsies from patients
with type 2 diabetes and diabetic nephropathy [50] and Aldose reductase expression and transgenesis
in glomerular lesions in experimental diabetes [51].
Renal osmolarity–dependent transcriptional regula-
tion of aldose reductase has been initially described inDicarbonyl and lipid dialdehyde substrates for
the renal medulla [55] and subsequently shown in severalaldose reductase
cell types including the rat kidney, renal medullary cells
Of immediate relevance to any consideration of the [56, 57], and mesangial cells [58]. In rat mesangial cells,
aldose reductase pathway in hyperglycemic conditions increased aldose reductase in response to glucose required
is the findings from many sources that the dicarbonyls, hypertonic levels (,600 mOsm/kg), seen with addition of
methylglyoxal and 3-deoxyglucasone, which contribute 300 mmol/L glucose, in one reported study [58]. How-
to glycoxidation products, and the lipid dialdehyde prod- ever, in cultured cells from nonrenal sources, increased
ucts of the oxidation of unsaturated fatty acids in mem- aldose reductase mRNA is seen at lower glucose concen-
trations. In cultured bovine endothelial cells, a glucosebrane and lipoprotein phospholipids (4-hydroxynonenal,
concentration of 18 mmol/L is effective [59] whereas informed by the oxidation of linoleic acid and acrolein
one fetal rat aortic smooth muscle cell line, A10, in-formed by the oxidation of arachidonic acid), which con-
creased transcription follows 80 mmol/L glucose [60] andtribute to lipoxidation adducts are most effective sub-
in a second line, A7r5, glucose increased aldose reduc-strates for aldose reductase [52, 53] with a substrate spec-
tase mRNA levels in a glucose concentration–dependentificity for a recombinant form of the enzyme higher than
manner up to 205.5 mmol/L [61]. Feeding galactose in-that for glucose (Fig. 2). Reactive endogenous aldehydes
creases the alcohol product galactitol following aldoseformed either nonoxidatively or oxidatively, including
reductase activation and produces a rapid polyol-depen-methylglyoxal, 3-deoxyglucosone, and 4-hydroxynonenal
dent regulation of aldose reductase gene expression in
inhibit glutathione reductase [54], which are required both the renal cortex and medulla [62]. An initial polyol-
for regeneration of reduced glutathione. Thus, aldose dependent decrease in renal papillary aldose reductase
reductase may modify formation of reactive dicarbonyl mRNA supports feedback regulation by the polyol prod-
compounds and lipid aldehydes and subsequently pro- uct [63] but sustained feeding with 50% galactose in-
tein-bound adducts associated with oxidative stress and creases whole kidney aldose reductase mRNA [64]. Strep-
tissue damage. This role for aldose reductase has not tozotocin-induced diabetes is associated with increased
been extensively investigated in diabetes. Possibly inter- renal aldose reductase gene expression [65] as is diabetes
related aspects of aldose reductase with glucose-medi- of 3 months duration in the diabetes-prone BB/wor rat [66]:
an implication that diabetes-related hyperglycemia orated metabolic changes leading to glycoxidation or lipox-
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Fig. 3. Glucose-driven formation of reactive
oxygen species, reactive dicarbonyls, and lipid
aldehydes that may be exacerbated or amelio-
rated in the presence of increased aldose re-
ductase activity. The relationship of the intra-
cellular events of the schema is expanded in
the text, wherein it is proposed that the poten-
tially exacerbating effects of aldose reductase
(AR, shown at 1) to increase in O2x, to decrease
reduced glutathione (GSH) availability, and
to provide triose phosphates (triose-P) through
activation of the pentose phosphate pathway
(PPP) as dicarbonyl precursors may be found
together with alleviating effects (shown at 2
and 3) that include the enzymatic reduction
of dicarbonyls including methylglyoxal (MG)
and 3-deoxyglucosone (3-DG) and lipid dial-
dehydes including 4-hydroxynonenal (4-HNE)
and acrolien. One outcome of any investiga-
tion into these diverse effects may be to pro-
vide an explanation for the plethora of con-
flicting data when aldose reductase inhibition
is applied clinically. A significant further out-
come of such studies might be the finding of
renal cell types with major susceptibility to
injury by dicarbonyl and oxidative stress and
for which general aldose reductase inhibition
may be an inappropriate therapy. This damage
could be prevented in the short term by an
optimized glucose level with or without anti-
oxidant protection but as a long-term goal
appropriately targeted aldose reductase inhi-
bition could be sought. Further abbreviations:
G–6–P, glucose–6–phosphate; GP, glutathi-
one peroxidase; GR, glutathione reductase;
GSSG, oxidized glutathione; SDH, sorbitol
dehydrogenase; SOD, superoxide dismutase.
hypertonicity stimulates aldose reductase gene expres- cell type as used in those studies, aldose reductase
mRNA induction is seen in response to oxidative stimulision. Characterizations of the promoter region of the al-
dose reductase gene have shown the presence of 59-flank- and found after both H2O2 and 4-hydroxynonenal [73].
In the Madin-Darby canine kidney cell line, hypertonicing sequence ,11 base-pair elements responding to
osmotic stimuli. This osmotic response element (ORE) activation induction of aldose reductase mRNA (and
ORE-driven reporter gene expression) is prevented byhas been reported for rabbit [67], human [68], mouse
[69], and rat [70] aldose reductase [71] each containing inhibition of p38-mitogen activated protein kinase (p38-
MAPK) and of mitogen-activated extracellular regulateda C/TGGAAAATCAC ([C] cytosine: rabbit. [T] thymi-
dine; human, mouse, and rat) nucleotide sequence con- kinase, with the indication that these two kinases are
involved in the regulation of the hyperosmotic stressferring an osmotic response. One report indicates that
in the sequence of human aldose reductase at least three response [74]. Similar studies in primary rat vascular
smooth muscle cells have shown that protein kinase C isORE sequences occur, none of which in isolation can
induce transcription [68]. A recent investigation of the involved in ORE-dependent control of aldose reductase
gene transcription [75]. Together with the involvementrat aldose reductase gene by deletion analysis shows the
requirement for ORE-like sequences as major cis-acting protein kinase C in oxidative stress conditions of raised
glucose [76] my own recent investigations and those ofelements but shows additionally that glucose results in
a greater fold induction of expression in response to others that show that experimental diabetes and raised
glucose [77, 78] or H2O2 [78] activate p38-MAPK in glo-glucose in comparison to other osmolytes [72]. Further,
because the augmented response to glucose was not seen meruli and mesangial cells, provides two potential mech-
anisms for glucose to contribute to an ORE-inducedwith non–cell permeable L-glucose or the nonmetaboliz-
able 3-0-methylglucose, a glucose-specific induction of activation of aldose reductase expression, which may or
may not require concomitant hyperosmotic conditions.aldose reductase expression, dependent on glucose me-
tabolism, was proposed by these authors. It may be of Two mouse lines, transgenic for human aldose reduc-
tase, have been reported. One, carrying the hAR2 cDNAconsiderable relevance that, in the same smooth muscle
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driven by the murine major histocompatibility class of human aldose reductase (hAR2) in this Tg-
CMVhAR2 transgenic rat could alter the local level of(MHC) class I molecule promoter, developed thrombo-
sis in renal vessels and deposits in Bowman’s capsule protection against glycoxidative and lipoxidative stress
in a physiologically relevant susceptible area. Some pre-similar to those of the diabetic exudative lesion after 6
weeks of a normal diet [79]. However, the presence of liminary data in support of this are presented below.
this transgene did not alter the course of galactose feed-
Carbonyl groups introduced into S3 tubule proteinsing–induced urinary albumin excretion [80], although
by a free radical stresstransgenic animals fed a galactose diet developed cata-
racts and occlusion of the retinochoroidal vessels [79]. An assay of carbonyl groups in proteins was used to
quantify oxidative modification of proteins in microdis-A second transgenic mouse line in which human AR
cDNA was linked to the mouse aA-crystallin promoter sected S3 proximal tubule segments that were taken from
PVG/c control or Tg-CMVhAR2 rats. The assay mea-and which demonstrated an increase in lens aldose reduc-
tase shows an accumulation of sorbitol to a high level sures protein-bound 2,4-dinitrophenylhydrazone formed
by a reaction of protein dicarbonyls with 2,4-dinitro-under hyperglycemic conditions and an acceleration in
diabetic cataract formation [81]. A recent finding in these phenylhydrazine (DNPH) after treatment with strepto-
mycin sulfate to remove contaminating nucleic acid [78].human aldose reductase-targeted lens showed that, in
addition to an osmotic stress, the polyol pathway is a Proteins from S3 tubules isolated from PVG/c control
animals contained significantly more DNPH-reactive di-major contributor to the generation of hyperglycemic
oxidative stress in lens, demonstrated by a decrease in carbonyl groups than S3 tubule segments isolated from
Tg-CMVhAR2 rats (4.0 6 0.22 vs. 2.9 6 0.30 nmol pro-reduced glutathione and a concomitant rise in a lipid
peroxidation product, malondialdehyde [82]. As an ex- tein bound dicarbonyl/mg protein, N 5 6; P , 0.01),
each group between 12 and 14 weeks of age. When S3perimental model, we have established a line of trans-
genic rats on a PVG/c strain background that express a tubules were exposed to H2O2 in vitro for 18 h, a significant
increase in protein-bound dicarbonyls was seen only intransgene consisting of human aldose reductase (hAR2)
cDNA placed under the control of the cytomegalovirus PVG/c control S3 tubules. In the presence of an aldose
reductase inhibitor (imirestat), however, protein-bound(CMV) promoter. The structure of the transgene, which
also contains an SV40 splice and polyadenylation signal dicarbonyls increased significantly in both PVG/c and Tg-
CMVhAR2 S3 tubule segments (Fig. 4). Thus, it couldregion, allows location of the renal transgene by in situ
hybridization of an antisense riboprobe to this transgene- be concluded that aldose reductase expression in the trans-
genic rat has modified accumulated protein dicarbonylsspecific region. In this transgenic line, glomerular expres-
sion was not pronounced and a distinct pattern of tubular and those found following an acute free radical stress.
location in an area corresponding to the transition of
Conclusions and future directionscortex to outer stripe of outer medulla was found. Homo-
geneous labeling of proximal tubules was compatible Based on the preceding review, it is possible for several
hyperglycemia-linked mechanisms to be proposed thatwith the histotopography of the straight (S3) proximal
tubule (data not shown). Some observations of the S3 would singly or in concert contribute to the functional
deficits seen in early renal complications in diabetes.tubule segment characteristics are relevant to this model.
The renal cortex-medullary outer stripe marks the transi- Evidence derived from experimental diabetes indicates
that aldose reductase may initiate a process favoringtion to an environment of increasing osmolarity. Most
earlier investigations in proximal tubule cells have in- both glycoxidative and lipoxidative changes that may be
damaging to renal microvascular, glomerular, and tubulevolved ischemic injury, either ischemia/reperfusion in
vivo or hypoxia/reoxygenation as an in vitro surrogate cells. Aldose reductase inhibition can delay or prevent
many early changes. However, when the effect of aldosein proximal tubule cell culture [83]. Here it can be shown
that an interaction between cells and the extracellular reductase inhibition on microalbuminuria, the earliest
manifestation of renal impairment at a glomerular andmatrix is required for proliferation and repair rather
than entry to an apoptotic pathway with cell loss [84]. tubule level, is investigated in experimental diabetes,
several studies, including those from our work, show thisWithin the nephron, S3 has the highest level of lipid
peroxides [85], has low level expression of superoxide inhibition to be effective in reducing microalbuminuria
in the short term [31] but without effect on longer-termdismutase gene expression [86], and further, is the major
site of cellular damage in ischemic/reperfusion injury administration [88]. In part, this may be due to a balance
between the detrimental consequences of the glucose[87]. The S3 region has not been investigated specifically
for aldose reductase content or activity. In situ hybridiza- metabolism through the aldose reductase pathway and
a cytoprotective effect of aldose reductase. Inhibition oftion localization studies did not show marked hybridiza-
tion in the putative S3 region for endogenous rat aldose the polyol pathway can prevent the formation of sorbitol
and fructose as well as alterations in pyridine nucleotidesreductase. It is possible to postulate that the expression
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way inhibition may not be expected to alter the
nonenzymatic formation of dicarbonyls nor the genera-
tion of free radicals from radical counteranions formed
during protein cross-linking. Lipid peroxidation by free
radical species may lead to a general or site-specific renal
insult. Moreover, 4-hydroxynonenal, a major lipid-per-
oxidation-derived aldehyde, has been shown to be cyto-
toxic to proximal tubule cells [89], it can also be shown
to be degraded in these cells [90]. Evidence is increasing
that aldose reductase-mediated metabolism is an impor-
tant component of 4-hydroxynonenal detoxification in
several tissues [91–94] including lipid-peroxidative vas-
cular wall injury [95]. When taken together, the potential
for the polyol pathway to exacerbate or to alleviate hy-
perglycemia-related injury, presents a challenge to target
the most appropriate tissue site, susceptible to modifica-
tions that over the long-term will provide protection
against hyperglycemia-related injury and renal complica-
tions.
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